WuXi XDC enters strategic collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform

CAR-T Digest - August 2020

27 February 2026: WuXi XDC enters strategic collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform

WuXi XDC has announced a strategic collaboration with Earendil Labs to advance next-generation antibody-drug conjugates (ADCs), combining WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform with Earendil’s AI-driven antibody discovery capabilities
Under the agreement, Earendil Labs will receive an exclusive global license to apply the WuXiTecan-2 technology across multiple targets, enabling the company to conjugate antibodies and bispecific antibodies generated from its AI platform and accelerate the development of novel ADC candidates
The collaboration carries a potential deal value of up to $885 million, including upfront payments and development, regulatory, and commercial milestone payments, with WuXi XDC also eligible to receive tiered royalties on future product sales
As part of the partnership, WuXi XDC will leverage its integrated CRDMO platform to support the chemical, manufacturing, and controls (CMC) development and production of ADC components, while Earendil Labs will lead clinical development, regulatory submissions, and commercialization globally
By combining AI-driven biologics discovery with advanced ADC payload-linker technology, the two companies aim to accelerate the development of safer and more effective ADC therapies for cancer, autoimmune diseases, and other conditions with significant unmet medical needs